Exelixis Reports Tomorrow With Competitive Questions It Has Not Yet Answered

Exelixis Inc (EXEL) reports first-quarter 2026 earnings after market close on Monday, May 5, 2026—just one day away. With the stock trading at $44.17 and analysts expecting $0.67 per share, the central question is whether the oncology-focused biotech can extend its remarkable streak of four consecutive earnings beats, each exceeding estimates by double digits. The answer will determine if EXEL can maintain momentum in a technical setup that has turned increasingly mixed heading into the print.

Part 1: Earnings Preview

Exelixis is a biotechnology company focused on the discovery, development, and commercialization of small molecule therapies for cancer, with its flagship product Cabometyx (cabozantinib) generating the majority of revenue across multiple indications including renal cell carcinoma and hepatocellular carcinoma. The company also has a growing pipeline of investigational compounds targeting various oncology pathways.

Analysts expect Exelixis to report $0.67 per share for the first quarter of 2026 when results are released after the close on May 5, 2026. The company most recently reported $0.88 per share for the fourth quarter of 2025, marking a substantial beat of the $0.68 consensus. Compared to the same quarter last year when EXEL earned $0.53 per share, the current estimate implies +26.42% year-over-year growth—a robust acceleration that reflects both Cabometyx's continued commercial strength and improving operating leverage.

Three key themes define this earnings story:

Cabometyx Commercial Momentum: The core question is whether Cabometyx can sustain its growth trajectory across existing indications while penetrating new treatment settings. Recent quarters have shown resilient demand despite increasing competition in the renal cell carcinoma space, and investors will scrutinize revenue guidance for signs of market share stability or erosion.

Pipeline Progress and Zanzalintinib Potential: Exelixis's investigational compound zanzalintinib (XL092) represents a potential next-generation franchise asset, with multiple ongoing trials in kidney cancer and other solid tumors. Any updates on clinical trial readouts, regulatory timelines, or partnership discussions could significantly impact the stock's valuation multiple, as the market seeks visibility beyond Cabometyx's patent life.

Margin Expansion and Capital Allocation: With four consecutive quarters of substantial earnings beats, the Street is watching whether EXEL can translate revenue growth into sustainable margin improvement. The company's approach to capital allocation—whether prioritizing pipeline investment, business development, or potential shareholder returns—will signal management's confidence in the durability of current profitability.

Analyst commentary ahead of the release reflects cautious optimism. The consensus has been gradually raising estimates, with the Q1 forecast climbing from $0.53 prior-year actual to $0.67 currently. However, the wide estimate range ($0.60 to $0.74) suggests meaningful uncertainty about near-term business trends. Several analysts have noted that Cabometyx's performance in competitive markets will be critical, while others emphasize that pipeline developments could provide upside catalysts independent of base-business results.

Part 2: Historical Earnings Performance

Exelixis has established an exceptional pattern of exceeding analyst expectations, delivering four consecutive quarterly beats with an average surprise of +26.62%. The most recent quarter (December 2025) saw the company report $0.88 per share against a consensus of $0.68, representing a +29.41% beat—the second-largest surprise in the trailing four quarters. This followed September's $0.67 result (+13.56% beat), June's $0.65 (+12.07%), and the remarkable March 2025 quarter when EXEL earned $0.53 versus the $0.35 estimate for a +51.43% surprise.

The magnitude and consistency of these beats suggest either persistent analyst conservatism or genuine operational outperformance that management has been unable to fully telegraph in guidance. Notably, the beat percentages have moderated from the extraordinary 51% surprise in Q1 2025 to the high-teens/low-twenties range in subsequent quarters, indicating estimates may be catching up to the company's improved earnings power. However, even the "smallest" recent beat of +12.07% in June 2025 represents a substantial margin of outperformance that would typically drive positive price action.

The trend is unambiguous: Exelixis has not missed estimates in any of the past four quarters, and the sequential earnings progression from $0.53 to $0.65 to $0.67 to $0.88 demonstrates accelerating profitability. This track record creates elevated expectations heading into Monday's report, where the $0.67 consensus represents a +26.42% year-over-year increase but would actually mark a sequential decline from the prior quarter's $0.88—a dynamic that could complicate the market's reaction even if the company beats estimates once again.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Exelixis reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

The historical price behavior reveals a stock that delivers dramatic post-earnings moves, though the direction has been highly variable. The average absolute Day +1 move of 9.60% significantly exceeds the Day 0 anticipatory move of just 1.21%, indicating that EXEL's earnings results consistently surprise the market in one direction or another. The Day +1 range of 8.33% further confirms substantial intraday volatility as investors reassess positions.

The most striking pattern is the binary nature of outcomes: three of the past eight earnings events produced Day +1 gains exceeding 12% (including a massive +20.84% surge in May 2025 and +13.09% in August 2024), while the July 2025 report triggered a brutal -16.78% decline. This suggests the market struggles to accurately price EXEL heading into results, creating opportunity for significant moves in either direction. Notably, Day 0 moves have been relatively muted (averaging just 1.21%), indicating limited information leakage and that the real action occurs after the actual print.

Investors should prepare for volatility: while the four-quarter beat streak might suggest upside bias, the historical average of 9.60% absolute movement means a swing of $4+ in either direction would be well within normal parameters. The July 2025 experience—where a beat still produced a double-digit decline—serves as a reminder that guidance and forward commentary can matter as much as the headline number.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 7.70% ($3.40) for the May 15 expiration, which sits below the historical average Day +1 move of 9.60% but well above the Day 0 average of 1.21%. This suggests options traders are anticipating meaningful volatility but may be underpricing the stock's tendency for outsized post-earnings swings, particularly given the recent pattern of 12%+ moves in three of the past eight reports.

Part 3: What Analysts Are Saying

Analyst sentiment on Exelixis reflects a divided Street with a slight bullish tilt. The current average recommendation of 3.90 (between Hold and Buy) is supported by 10 Strong Buy ratings and 10 Hold ratings, with just 1 Moderate Sell and zero Strong Sells among the 21 analysts covering the stock. The consensus price target of $47.53 implies +7.6% upside from the current $44.17 price, with a wide range spanning from a low of $35.00 (-20.8%) to a high of $60.00 (+35.8%).

Sentiment has improved over the past month, with the average recommendation ticking up from 3.86 to 3.90, though the Hold count declined by one from 11 to 10. This modest shift suggests analysts are becoming incrementally more constructive, likely reflecting confidence in the company's ability to continue beating estimates and execute on its commercial and pipeline strategies. The concentration of ratings at the extremes—10 Strong Buys versus 10 Holds—indicates a polarized view where bulls see significant upside from pipeline optionality and margin expansion, while more cautious analysts question the sustainability of Cabometyx growth and the timeline for meaningful pipeline contributions.

The $47.53 mean target represents a relatively modest premium to the current price, suggesting the Street believes much of the recent operational success is already reflected in the valuation. However, the $60 high target from the most bullish analysts implies that a strong earnings print coupled with positive pipeline updates could unlock another 35%+ upside if the company can demonstrate durability beyond its core franchise.

Part 4: Technical Picture

The Barchart Technical Opinion currently registers a 72% Buy signal, down from 88% Buy one week ago and up from 48% Buy one month ago, indicating recent weakening in near-term momentum despite a generally constructive intermediate-term setup. This deterioration in the weekly signal suggests some technical damage heading into Monday's earnings release.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has cooled considerably from the stronger readings seen earlier, reflecting recent price weakness
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive but lacks conviction, with the stock consolidating recent gains
• Long-term (100% Buy): Strong buy signal confirms the longer-term uptrend remains intact, providing a supportive backdrop for patient holders

Trend Characteristics: The Average strength trend that is Weakening suggests EXEL is losing momentum at a critical juncture, with the technical setup becoming less supportive just as the company prepares to report earnings.

The stock is trading at $44.17, positioned below its 5-day ($44.39), 10-day ($45.03), and 20-day ($44.81) moving averages—a bearish short-term configuration that indicates recent selling pressure. However, EXEL remains above its 50-day ($43.31), 100-day ($43.46), and 200-day ($41.68) moving averages, confirming the longer-term uptrend remains intact despite near-term weakness.

The technical picture heading into earnings is mixed: while the longer-term trend structure remains supportive with the stock holding above all major moving averages beyond 20 days, the recent breakdown below short-term averages and deteriorating momentum signals suggest vulnerability. The $43.31 fifty-day moving average represents critical support—a break below on disappointing results could trigger a deeper correction toward the $41.68 two-hundred-day average. Conversely, a strong beat that reclaims the $45.03 ten-day average would likely trigger a technical breakout given the compressed trading range. The weakening trend characteristics suggest the path of least resistance may be lower absent a significant positive catalyst from Monday's report.